{"metadata": {"source": "pubchem", "title": "Methamphetamine | C10H15N | CID 10836 - PubChem", "description": "Methamphetamine | C10H15N | CID 10836 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/10836", "drug": "Methamphetamine", "cid": 10836, "char_count": 131280, "word_count": 16880, "doc_id": "doc_35", "num_chunks": 185, "chunk_id": "35::chunk_55", "document_index": 35, "latency_s": 1.5586543999961577, "prompt_toks": 33662, "completion_toks": 72, "relevance_score": 3.576359e-07}, "content": "Drug: Methamphetamine | cid: 10836\nSource: pubchem | Source description: Methamphetamine | C10H15N | CID 10836 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    and increased again as drug makers circumvented precursor restrictions (2008-2012). Seven percent of meth-related chemical incidents resulted in injuries to 162 persons, mostly members of the general public (97 persons, including 26 children) and law enforcement officials (42). Recent trends suggest a need for efforts to protect the general public, particularly children and law enforcement officials. Because individual state legislative actions can result in increased illegal meth production in neighboring states, a regional approach to prevention is recommended.\n\n\n                    Context: \n                    This excerpt summarizes recent trends in methamphetamine manufacturing and associated chemical incidents, highlighting increased circumventing of precursor restrictions between 2008-2012 and the resulting injuries, predominantly affecting the public and law enforcement. It underscores the importance of regional prevention efforts and situates within the broader discussion of illicit production, safety hazards, and regulatory challenges covered in the full document.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Oxycodone (Percocet, Oxycontin) Vault: Basics", "description": "A summary of basic information about Oxycodone (Percocet, Oxycontin) and its use.", "language": "No language found.", "url": "https://www.erowid.org/pharms/oxycodone/oxycodone_basics.shtml", "drug": "Oxycodone", "cid": 5284603, "substance": "oxycodone", "category": "PHARMS", "erowid_column": "Basics", "char_count": 8952, "word_count": 1276, "doc_id": "doc_213", "num_chunks": 12, "chunk_id": "213::chunk_6", "document_index": 213, "latency_s": 0.7535525999992387, "prompt_toks": 2609, "completion_toks": 48, "relevance_score": 3.576359e-07}, "content": "Drug: Oxycodone | cid: 5284603\nSource: erowid | Source description: A summary of basic information about Oxycodone (Percocet, Oxycontin) and its use.\nErowid name: oxycodone\nCategory: PHARMS\nField: Basics\n\n                    Text: \n                    Price #\n\nPrescription prices vary but have increased since the introduction of the gummy anti-injection/anti-snorting versions of Oxycodone tablets. Prices in the U.S. are in the range of $5-10 per 40 mg tablet in the United States (2013), with street prices around $1 USD per mg ($40 per 40mg tablet). Canadian prices are around 1.25-1.75 CDN per mg for OxyNeo and 2-2.5 CDN per millligram of oxycodone. much lower.\n\nLaw #\n\nOxycodone is available by prescription only in most countries. It is Schedule II in the United States, making it illegal to sell without a license and illegal to purchase or possess without a prescription.\n\nChemistry #\n\nOxycodone is an opioid analgesic, closely related chemically to opioids such as codeine and morphine.\n\nPharmacology #\n\nAs with most other opioids, oxycodone's mechanism of analgesic action is unknown. It is presumed to work by affecting opioid receptors found in the brain.\n\nProduction #\n\n\n                    Context: \n                    This section provides detailed information on oxycodone’s pricing, legal status, chemical properties, pharmacology, and production, offering essential data for understanding its market, regulatory classification, and biochemical nature within the comprehensive Erowid drug overview.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Methamphetamine Vault : Timeline", "description": "A timeline of events in the history of Amphetamines", "language": "No language found.", "url": "https://www.erowid.org/chemicals/meth/meth_timeline.php", "drug": "Methamphetamine", "cid": 10836, "substance": "meth", "category": "CHEMICALS", "erowid_column": "History", "char_count": 11550, "word_count": 1658, "doc_id": "doc_203", "num_chunks": 15, "chunk_id": "203::chunk_12", "document_index": 203, "latency_s": 0.8428323999978602, "prompt_toks": 3217, "completion_toks": 90, "relevance_score": 3.2058276e-07}, "content": "Drug: Methamphetamine | cid: 10836\nSource: erowid | Source description: A timeline of events in the history of Amphetamines\nErowid name: meth\nCategory: CHEMICALS\nField: History\n\n                    Text: \n                    Methamphetamine Epidemic Act of 2005\" provides for criminal penalties for non-compliance with the DEA rules and limits maximum amount any individual can purchase per month to 9 grams. Jul 2, 2007 Lisdexamfetamine dimesylate is released onto the market under the trade name Vyvanse by Shire.  Their goal is/was to have Vyvanse take Adderall XR's place as the top-selling ADHD medicine [in the U.S.]. [More Info] 2011 The United Nations Office on Drugs and Crime declares that 2011 saw the highest level of law enforcement seizures of amphetamine-type stimulants in history. Global amphetamine-type stimulant ATS seizures rise to highest level ever recorded. [...] The overall increase in ATS seizures is mainly due to surging methamphetamine seizures, which grew by 73 per cent from 51 tons in 2010 to 88 tons in 2011. 9\n\n\n                    Context: \n                    This chunk summarizes key recent developments in methamphetamine regulation and global enforcement, including the 2005 Methamphetamine Epidemic Act establishing purchase limits and criminal penalties, the 2007 market release of Vyvanse as a top ADHD medication, and the 2011 record-high global seizures of amphetamine-type stimulants driven mainly by increased methamphetamine confiscations. It provides current legal and enforcement context within the broader discussion of methamphetamine history and law.\n                "}
